208 related articles for article (PubMed ID: 27120790)
1. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y; Tatzel K; Wang X; Belt B; Binder P; Kuroki L; Powell MA; Mutch DG; Hawkins WG; Spitzer D
Oncotarget; 2016 May; 7(21):31534-49. PubMed ID: 27120790
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
3. A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing.
Spitzer D; McDunn JE; Plambeck-Suess S; Goedegebuure PS; Hotchkiss RS; Hawkins WG
Mol Cancer Ther; 2010 Jul; 9(7):2142-51. PubMed ID: 20571073
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.
Kuroki LM; Jin X; Dmitriev IP; Kashentseva EA; Powell MA; Mutch DG; Dietz AB; Curiel DT; Hawkins WG; Spitzer D
PLoS One; 2017; 12(12):e0190125. PubMed ID: 29267342
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
6. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.
Matte I; Lane D; Boivin M; Rancourt C; Piché A
BMC Cancer; 2014 Apr; 14():234. PubMed ID: 24690311
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
8. Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.
Tatzel K; Kuroki L; Dmitriev I; Kashentseva E; Curiel DT; Goedegebuure SP; Powell MA; Mutch DG; Hawkins WG; Spitzer D
Sci Rep; 2016 Mar; 6():22661. PubMed ID: 26935795
[TBL] [Abstract][Full Text] [Related]
9. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
Bruney L; Conley KC; Moss NM; Liu Y; Stack MS
Biol Chem; 2014 Oct; 395(10):1221-31. PubMed ID: 25205731
[TBL] [Abstract][Full Text] [Related]
10. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.
Lakshmanan I; Ponnusamy MP; Das S; Chakraborty S; Haridas D; Mukhopadhyay P; Lele SM; Batra SK
Oncogene; 2012 Feb; 31(7):805-17. PubMed ID: 21785467
[TBL] [Abstract][Full Text] [Related]
11. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
12. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
13. A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo.
Rozanov D; Spellman P; Savinov A; Strongin AY
PLoS One; 2015; 10(4):e0122980. PubMed ID: 25849628
[TBL] [Abstract][Full Text] [Related]
14. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Boivin M; Lane D; Piché A; Rancourt C
Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
[TBL] [Abstract][Full Text] [Related]
15. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
16. Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
Rao TD; Rosales N; Spriggs DR
Mol Cancer Ther; 2011 Oct; 10(10):1939-48. PubMed ID: 21817115
[TBL] [Abstract][Full Text] [Related]
17. Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.
Rozga P; Kloska D; Pawlak S; Teska-Kaminska M; Galazka M; Bukato K; Pieczykolan A; Jaworski A; Molga-Kaczmarska A; Kopacz A; Badyra B; Kachamakova-Trojanowska N; Zolnierkiewicz O; Targosz-Korecka M; Poleszak K; Szymanik M; Zerek B; Pieczykolan J; Jozkowicz A; Grochot-Przeczek A
Int J Cancer; 2020 Aug; 147(4):1117-1130. PubMed ID: 31863596
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models.
Kopczynski M; Statkiewicz M; Cybulska M; Kuklinska U; Unrug-Bielawska K; Sandowska-Markiewicz Z; Grochowska A; Gajewska M; Kulecka M; Ostrowski J; Mikula M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808900
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
20. Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.
Yan J; Wang L; Wang Z; Wang Z; Wang B; Zhu R; Bi J; Wu J; Zhang H; Wu H; Yu B; Kong W; Yu X
Cell Death Dis; 2016 Jun; 7(6):e2274. PubMed ID: 27336718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
